Tardive Dyskinesia Lawsuit News and Information
Reglan Lawsuits
Reglan side effects have been associated with the development of tardive dyskinesia, a syndrome that causes involuntary movements in the body extremities, particularly the lower face. In February 2009, the FDA required that a “black box” warning about the tardive dyskinesia problems be added to Reglan and other gastrointestinal drugs containing metoclopramide.
All Articles Tagged With: "Tardive Dyskinesia"
AstraZeneca Successful in First Diabetes Seroquel Lawsuit
A New Jersey jury has handed drug maker AstraZeneca a defense verdict in the first trial over claims that side effects of Seroquel, a popular atypical antipsychotic, caused users to develop diabetes.
Seroquel Litigation May Cost AstraZeneca $1.2B in Legal Costs: Report
Litigation over Seroquel could cost AstraZeneca up to $1.2 billion in legal costs between thousands of plaintiffs’ failure-to-warn Seroquel lawsuits and government charges that the popular anti-psychotic drug was marketed illegally.
Generic Reglan Tardive Dyskinesia Lawsuit Not Preempted: Appeals Court
The U.S. Court of Appeals for the Firth Circuit has rejected the argument by a generic drug maker that federal law preempts a state-law failure-to-warn claim filed by a user of their generic Reglan, who developed the rare movement disorder tardive dyskinesia.
Two Seroquel Lawsuits in Delaware Dismissed, First New Jersey Trial Nears
A Delaware state court judge has dismissed two Seroquel lawsuits after excluding the plaintiffs’ expert witness testimony, leaving the plaintiffs with no way to prove that their use of Seroquel caused diabetes. However, the ruling is specific to these two cases and will not have a direct impact on thousands of other similar lawsuits [...]
Reglan Lawsuit Over Use of Generics Results in Dismissal of Original Makers
Wyeth, Inc. and Schwarz Pharma, Inc. have been dismissed from a Reglan lawsuit filed by a woman who developed a rare movement disorder, known as tardive dyskinsia, after using a generic version of their gastrointestinal drug. The failure to warn case will now proceed against only the makers of generic Reglan.
Seroquel Settlement Talks Ordered by Federal Judge in Diabetes Suits
The judge who is overseeing all of the federal Seroquel suits, which were filed by former users of the antipsychotic who developed diabetes and other injuries, is recommending that as many as 6,000 cases be sent back to the districts where they were originally filed for trial. Lawyers for both sides have also been [...]
Seroquel Settlement for $520M Reached with Federal Prosecutors
According to a quarterly report released by AstraZenca, the drug maker has reached an agreement in principal to pay $520 million to settle a Seroquel probe by the U.S. Attorney’s Office in Philadelphia over their alleged off-label promotion of the atypical antipsychotic drug for uses that were not established as safe and effective through the [...]
Drug Maker Sues FDA Over Ban on Offering Doctors Info About Off-Label Uses
The makers of Botox filed a lawsuit last week against the FDA, challenging federal regulations that ban drug companies from marketing drugs for uses that they have not been established as safe and effective through the FDA approval process.
Generic Seroquel Held Off by US Appeals Court
The U.S. Court of Appeals for the Federal Circuit has rejected attempts by generic drug makers to invalidate AstraZeneca’s patent on the atypical antipsychotic drug Seroquel, meaning that generic versions of the drug will not be available until the patent expires in September 2011, with pediatric exclusivity extending through March 2012.
Seroquel Diabetes Side Effects Kept from U.S. Doctors
Internal documents from AstraZeneca suggest that the pharmaceutical giant did not tell doctors in the United States about Seroquel diabetes side effects, even after it admitted to doctors in Japan that there was likely a connection between the antipsychotic drug and increased risk of diabetes in users.
Contact a Lawyer
Submit information about your potential case to be reviewed by an attorney.
